Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

An Australian vote for pharma: biosimilars

This article was originally published in Scrip

Executive Summary

Somatropin is the only biosimilar product on the Australian market. (In Europe, by contrast, 17 biosimilars of five different molecules have been approved since 2006.) This synthetic growth hormone recorded sales of $45,000 in 2009, although the market is still very much dominated by the original branded product: Pfizer's Genotropin and Genotropin MiniQuick. Three years after the first biosimilar was launched, the biosimilar somatropin market accounted for 0.4% of total somatropin sales.

You may also be interested in...



Coronavirus Update: Lilly Begins Clinical Trial Of Antibody Therapy

Discovered at record-breaking speed by AbCellera, Lilly says the antibody candidate could progress into Phase II trials by June.

Metformin Testing Prompts New Finding Of NDMA And Cancer Risk

The US FDA requests several manufacturers recall extended-release metformin based on studies confirming a higher NDMA impurity threshhold; previous testing found no significant risks.

Remdesivir India Sub-Licensing: Gilead Indicates Conditional Position For Subcontracting

Gilead clarifies position on Cipla’s sub-licensing effort for remdesivir, the investigational antiviral in the global spotlight as a potential treatment for COVID-19.

Topics

Related Companies

UsernamePublicRestriction

Register

MT012180

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel